An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer

European Journal of Cancer ◽

10.1016/j.ejca.2015.05.020 ◽

2015 ◽

Vol 51 (12) ◽

pp. 1588-1595 ◽

Author(s):

Sun Min Lim ◽

Woong Youn Chung ◽

Kee-Hyun Nam ◽

Sang-Wook Kang ◽

Jae Yun Lim ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase ◽

Advanced Thyroid Cancer

Download Full-text

Phase II study: aclarubicin in advanced thyroid cancer

Acta Endocrinologica ◽

10.1530/acta.0.117s144 ◽

1988 ◽

Vol 117 (4_Suppl) ◽

pp. S144

Author(s):

H. SAMONIGG ◽

D.K. HOSSFELD ◽

J. SPEHN ◽

H. FILL ◽

G. LEB

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Thyroid Cancer

Download Full-text

Faculty Opinions recommendation of Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1113124.569114 ◽

2008 ◽

Author(s):

Luca Persani ◽

Laura Fugazzola

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Active Treatment ◽

Phase Ii Study ◽

Advanced Thyroid Cancer ◽

Histologic Subtypes

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.14684 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 14684-14684 ◽

Author(s):

M. E. Pavel ◽

C. Bartel ◽

F. Heuck ◽

F. Neumann ◽

N. Tiling ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Angiogenesis Inhibitor ◽

Multicenter Phase ◽

Neuroendocrine Carcinomas

Download Full-text

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.9033 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 9033-9033 ◽

Author(s):

R. Dummer ◽

C. Robert ◽

P. B. Chapman ◽

J. A. Sosman ◽

M. Middleton ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Advanced Melanoma ◽

Multicenter Phase

Download Full-text

ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8060 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8060-8060 ◽

Author(s):

Enriqueta Felip ◽

Sergey Orlov ◽

Keunchil Park ◽

Chong-Jen Yu ◽

Chun-Ming Tsai ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Adult Patients ◽

Small Cell Lung ◽

Multicenter Phase

Download Full-text

A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer

Thyroid ◽

10.1089/thy.2007.0120 ◽

2008 ◽

Vol 18 (3) ◽

pp. 317-323 ◽

Author(s):

Nathan A. Pennell ◽

Gilbert H. Daniels ◽

Robert I. Haddad ◽

Douglas S. Ross ◽

Tracey Evans ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Thyroid Cancer

Download Full-text

857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.150 ◽

2021 ◽

Vol 32 ◽

pp. S784-S785

Author(s):

S. Ailawadhi ◽

A. Chanan-Khan ◽

J. Peterson ◽

P. Stiff ◽

E. Ibrahim ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

B Cell Malignancies ◽

Waldenström Macroglobulinemia ◽

Multicenter Phase ◽

Waldenstrom Macroglobulinemia ◽

Expansion Cohort

Download Full-text

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-2488 ◽

2020 ◽

Vol 27 (1) ◽

pp. 43-51

Author(s):

Xinan Sheng ◽

Xieqiao Yan ◽

Lin Wang ◽

Yanxia Shi ◽

Xin Yao ◽

...

Keyword(s):

Urothelial Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Multicenter Phase ◽

Metastatic Urothelial Carcinoma ◽

Download Full-text

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text